RiVax is Soligenix's proprietary vaccine developed to protect against exposure to ricin toxin and is the most advanced vaccine in the company's portfolio. RiVax induces a protective immune response in animal models of ricin exposure and is currently being evaluated in humans. One human Phase 1 clinical trial has been completed and a second trial is currently being conducted.
Results of the first Phase 1 clinical trial of RiVax established that the immunogen was safe and induced antibodies anticipated to protect humans from ricin exposure. The outcome of the study was published in 2006 in the Proceedings of the National Academy of Sciences. The second trial is currently evaluating a more potent formulation of RiVax. Soligenix has developed processes for large-scale manufacturing and is further establishing correlates of the human immune response in non-human primates.